BBIO BridgeBio Pharma Inc

William Blair reit'd $BBIO OP/said While the focus has been on Attruby, the company is poised to launch three additional products over the next year and sees an additional $4 billion in de-risked peak sales opportunity across the three. $ALNY $PFE BAYRY NPPNY SRPT William Blair added We continue to believe these clinically de-risked opportunities are being overlooked by the Street and that shares are undervalued for the top-line growth profile and view BridgeBio as becoming a core smid-cap biotech holding. We reiterate our Outperform rating.

Jefferies reiterated $BBIO Buy-$110 ~Has >90% in Full Approval—says its $1B+ Peak Sales Seem Conservative. $BAYRY $NPPNY SRPT ALNY PFE Jefferies said in its notez: New Phase III analyses support BBP-418's (oral substrate) disease-modifying potential in LGMD21/R9 (a rare muscle disease), reinforcing our 90%+ conviction in a full approval by its Nov 27, 2026 PDUFA. In short, '418 shows troponin/LVEF cardiac benefits, building on prior (+) findings across biomarkers and function (e.g. 100MTT, FVC). Net-net, our $1B+ peak sales seem conservative, since '418 has pot'l pricing power and is expanding into LGMD2M/2U and Fukuyama.

$BBIO BridgeBio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasi The FDA set a PDUFA target action date of February 4, 2027. If approved, infigratinib would be the first oral therapy for achondroplasia. In the Phase 3 PROPEL 3 trial it showed a mean height-velocity gain of +2.10 cm a year over placebo (p<0.0001).

$BBIO Still on track to become a significant bio player. The next 18 months should be a wild ride.

$BBIO 2 headlines here today. Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records "In an independent, propensity score-matched analysis of 2,684 individuals living with ATTR-CM from Epic COSMOS, the largest U.S. electronic health record database, acoramidis was associated with a statistically significant 18% lower risk of a composite of death, all-cause hospitalization, new-onset atrial fibrillation, and diuretic intensification versus tafamidis (HR 0.82; 95% CI 0.73-0.93; p<0.01)" Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1 "100% of participants who received encaleret reported improvements in at least one ADH1 symptom compared to 46% of participants who received standard of care today presented bone turnover results and patient-reported outcomes from the Phase 3 CALIBRATE trial of encaleret in autosomal dominant hypocalcemia type 1 (ADH1). The data were presented in oral presentations at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting in Boston, Massachusetts. Additionally, the Company dosed the first participant in RECLAIM-HP, its registrational Phase 3 study of encaleret in adults and adolescents with chronic hypoparathyroidism."

$BBIO 🏥 BridgeBio Pharma, Inc. reported Phase 3 CALIBRATE trial results showing encaleret increased bone turnover and improved ADH1 symptoms in 100% of participants versus 46% on standard of care, and the FDA accepted its NDA with Priority Review and a PDUFA date of May 8, 2027.

40 days out and $BBIO still isn't getting talked about like a name with a clean Phase 3 win in hand Nov 27 PDUFA BBP 418 for LGMD2I R9 Priority Review FORTIFY met every primary and secondary endpoint at the 12 month interim, treated patients improving while placebo declined if approved it's the first therapy for any form of LGMD. ngl that part matters more than the usual label guessing

$BBIO In the Aug 10th press release that announced Q2 earnings there was a note "BridgeBio will host a Commercial Day in New York City on October 8, 2026, to discuss commercial readiness and launch strategy across its three upcoming launches" Does anyone know if this is still happening and will they webcast this event. I can't find a link anywhere.

$BBIO Bullish Harami Candlestick Pattern Formed at Downtrend. Wait for the confirmation from the next day's candle. Bullish Harami is a two-candle reversal pattern where a small bullish candle forms within the body of a larger bearish candle, indicating a possible bullish reversal.